BRISTOL-MYERS SQUIBB COMPANY Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount
BRISTOL-MYERS SQUIBB COMPANY (BMY) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount of $12.10 billion for the 9-month period ending 2024-09-30, per its 10-Q filed 2024-10-31.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationNondeductibleExpense · last filed 2024-10-31
- BRISTOL-MYERS SQUIBB COMPANY effective income tax rate reconciliation, nondeductible expense, amount for the quarter ending 2024-09-30 was $0.00.
- BRISTOL-MYERS SQUIBB COMPANY effective income tax rate reconciliation, nondeductible expense, amount for the quarter ending 2024-06-30 was $0.00.
- BRISTOL-MYERS SQUIBB COMPANY effective income tax rate reconciliation, nondeductible expense, amount for the quarter ending 2024-03-31 was $12.10B.
- BRISTOL-MYERS SQUIBB COMPANY effective income tax rate reconciliation, nondeductible expense, amount for fiscal 2023 was $0.00.
- BRISTOL-MYERS SQUIBB COMPANY effective income tax rate reconciliation, nondeductible expense, amount for fiscal 2022 was $0.00.
- BRISTOL-MYERS SQUIBB COMPANY effective income tax rate reconciliation, nondeductible expense, amount for fiscal 2021 was -$108.00M.
- BRISTOL-MYERS SQUIBB COMPANY effective income tax rate reconciliation, nondeductible expense, amount for fiscal 2020 was -$363.00M, a 430.00% decline from fiscal 2019.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount 3 month | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount 6 month | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount 9 month | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount 12 month |
|---|---|---|---|---|
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-31 | $0.00 derived: sum of 2 quarters · filed 2024-10-31 | $12.10B 10-Q · filed 2024-10-31 | |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-07-26 | $12.10B 10-Q · filed 2024-07-26 | ||
| 2024-03-31 | $12.10B 10-Q · filed 2024-04-25 | |||
| 2023-12-31 | $0.00 10-K · filed 2024-02-13 | |||
| 2022-12-31 | $0.00 10-K · filed 2024-02-13 | |||
| 2021-12-31 | -$108.00M 10-K · filed 2024-02-13 | |||
| 2020-12-31 | -$363.00M 10-K · filed 2023-02-14 | |||
| 2019-12-31 | $110.00M 10-K · filed 2022-02-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |